Emmecell Completes Final Cell Therapy Dosing in U.S. Clinical Trial for Corneal Edema

Emmetrope Ophthalmics LLC, operating as Emmecell, a biotechnology firm in the clinical stage, announced the completion of the final dose administration in its U.S. clinical trial for EO2002, their innovative cell therapy designed for corneal edema treatment. The trial was randomized, double-masked, and multi-center in nature, testing both the safety and efficacy of the therapy.

EO2002 utilizes the unique Magnetic Cell Delivery (MCD) nanotechnology platform, offering a non-surgical method that might avoid the risks associated with corneal transplantation, which currently is the only option for approximately 10% of corneal edema patients with severe symptoms.

The company anticipates topline results from the trial in the latter half of 2024, with plans for a phase 3 pivotal study by early 2025. Sumit Garg, MD, Chair of the Emmecell Cornea Advisory Board, emphasized the study's role in potentially treating corneal endothelial dysfunction non-surgically across a wide spectrum of corneal edema intensity.

Noelia Kunzevitzky, PhD, COO of Emmecell, expressed gratitude towards all partners involved, highlighting the collective effort in advancing this non-surgical therapy aimed at globally addressing corneal blindness. Emmecell has also partnered with Eversight, a noted global nonprofit eye bank, reinforcing its commitment to combating blindness through advanced cell therapies like EO2002.